In Vitro Study of Combined Application of Bevacizumab and 5-Fluorouracil or Bevacizumab and Mitomycin C to Inhibit Scar Formation in Glaucoma Filtration Surgery

Table 4

Cell viability of human umbilical vein endothelial cells (HUVECs) after treatment with bevacizumab (BVZ), 5-fluorouracil (5-Fu), BVZ/5-Fu, mitomycin C (MMC), and BVZ/MMC.

Medicine and concentration (mg/ml)		Absorbance at 570 nm (ratio, compared to PBS)	Medicine and concentration (mg/ml)		Absorbance at 570 nm (ratio, compared to PBS)
BVZ	0.025	1.0652 ± 0.0792
	0.25	1.0030 ± 0.0598
	2.5	1.1882 ± 0.0699
5-Fu	0.05	0.9645 ± 0.0739	BVZ2.5/5-Fu	0.05	0.7194 ± 0.0929
	0.5	0.9938 ± 0.0492		0.5	0.6249 ± 0.0701
	5	0.8967 ± 0.0172		5	0.4385 ± 0.0108
MMC	0.00002	1.1165 ± 0.0726	BVZ2.5/MMC	0.00002	0.5989 ± 0.0734
	0.0002	1.0582 ± 0.1162		0.0002	0.6698 ± 0.0960
	0.002	0.9254 ± 0.0676		0.002	0.6613 ± 0.1846